{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:11:54Z","timestamp":1787587914194,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Shanghai Geriatrics Medical Center Institutional Project","award":["YM2025-005"],"award-info":[{"award-number":["YM2025-005"]}]},{"name":"National Natural Science Foundation of China, Youth Project","award":["No.: 82203403"],"award-info":[{"award-number":["No.: 82203403"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81972409, 81672549"],"award-info":[{"award-number":["No. 81972409, 81672549"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Poly (ADP-ribose) polymerase inhibitor (PARPi) resistance poses a significant challenge in prostate cancer (PCa). Although branched-chain amino acid (BCAA) metabolism is implicated in cancer biology, its specific role in PARPi resistance remains unclear. This study aims to investigate how BCAA metabolism contributes to PARPi resistance in PCa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We compared BCAA and Branched-Chain Amino Acid Aminotransferase 2 (BCAT2) levels between PARPi-resistant and PARPi-sensitive cell lines and assessed their clinical relevance. Functional studies were conducted in vitro and in vivo using cell and mouse models. Mechanistic assays, including RNA sequencing, metabolomics, RNA-binding protein immunoprecipitation (RIP), chromatin immunoprecipitation (ChIP), and Cleavage Under Targets and Tagmentation (CUT&amp;Tag), were used to delineate BCAT2-mediated PARPi resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>BCAT2 expression correlated with PARPi resistance in PCa, and increased BCAA\/BCAT2 levels in PARPi-resistant tissues were associated with reduced patient survival. Mechanistically, the DNA-binding domain (DBD) of PARP1 directly bound BCAT2 mRNA and regulated its stability; PARPi-induced PARP1 trapping weakened this interaction, increased BCAT2 expression, and promoted resistance. Transcriptomic and energy-metabolism analyses indicated that BCAT2 enhanced ABCG1 transcription by augmenting glycolysis and lactate secretion, thereby increasing histone H3K18la lactylation. These findings support a PARP1\u2013BCAT2\u2013ABCG1 axis in PARPi resistance. Combining a BCAT2 inhibitor with PARPi produced synergistic effects in cell line\u2013derived xenografts (CDXs) and patient-derived organoids (PDOs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The PARP1\u2013BCAT2\/H3K18la\u2013ABCG1 axis drives PARPi resistance in PCa. Targeted BCAT2 inhibition may enhance the therapeutic efficacy of PARPi.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-026-03719-1","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T02:04:08Z","timestamp":1778465048000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["PARP1-BCAT2 axis upregulates ABCG1 via histone lactylation to drive acquired PARP inhibitor resistance in prostate cancer"],"prefix":"10.1186","volume":"45","author":[{"given":"Wangli","family":"Mei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaozhi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyu","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanwen","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weitian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiqi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"3719_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10\u201345. https:\/\/doi.org\/10.3322\/caac.21871. PubMed: 39817679.","journal-title":"CA Cancer J Clin"},{"key":"3719_CR2","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/cac2.12321","volume":"42","author":"L Wu","year":"2022","unstructured":"Wu L, et al. The establishment of polypeptide PSMA-targeted chimeric antigen receptor-engineered natural killer cells for castration-resistant prostate cancer and the induction of ferroptosis-related cell death. Cancer Commun (Lond). 2022;42:768\u201383. https:\/\/doi.org\/10.1002\/cac2.12321. PubMed: 35706368.","journal-title":"Cancer Commun (Lond)"},{"key":"3719_CR3","doi-asserted-by":"publisher","first-page":"e12312","DOI":"10.1002\/jev2.12312","volume":"12","author":"F Urabe","year":"2023","unstructured":"Urabe F, et al. Metastatic prostate cancer-derived extracellular vesicles facilitate osteoclastogenesis by transferring the CDCP1 protein. J Extracell Vesicles. 2023;12:e12312. https:\/\/doi.org\/10.1002\/jev2.12312. PubMed: 36880252.","journal-title":"J Extracell Vesicles"},{"key":"3719_CR4","doi-asserted-by":"publisher","unstructured":"Karbach J, et al. Tumor-infiltrating lymphocytes mediate complete and durable remission in a patient with NY-ESO-1 expressing prostate cancer. J Immunother Cancer. 2023;11(e005847). https:\/\/doi.org\/10.1136\/jitc-2022-005847. PubMed: 36627144.","DOI":"10.1136\/jitc-2022-005847"},{"key":"3719_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.annonc.2019.09.007","volume":"31","author":"JM Genkinger","year":"2020","unstructured":"Genkinger JM et al. Measures of body fatness and height in early and mid-to-late adulthood and prostate cancer: Risk and mortality in the Pooling Project of Prospective Studies of Diet and Cancer. Ann Oncol. 2020;31:103\u2013114. https:\/\/doi.org\/10.1016\/j.annonc.2019.09.007. PubMed: 31912782.","journal-title":"Ann Oncol"},{"key":"3719_CR6","doi-asserted-by":"publisher","first-page":"e2110950","DOI":"10.1001\/jamanetworkopen.2021.10950","volume":"4","author":"CJD Wallis","year":"2021","unstructured":"Wallis CJD et al. Olaparib vs cabazitaxel in metastatic castration-resistant prostate cancer. JAMA Netw Open. 2021;4:e2110950. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.10950. PubMed: 34028551.","journal-title":"JAMA Netw Open"},{"key":"3719_CR7","doi-asserted-by":"publisher","unstructured":"He Y, et al. Targeting signaling pathways in prostate cancer: Mechanisms and clinical trials. Signal Transduct Target Ther. 2022;7(198). https:\/\/doi.org\/10.1038\/s41392-022-01042-7. PubMed: 35750683.","DOI":"10.1038\/s41392-022-01042-7"},{"key":"3719_CR8","doi-asserted-by":"publisher","unstructured":"G\u00f6kba\u011f B, et al. SLKB: synthetic lethality knowledge base. Nucleic Acids Res. 2024;52(D1418\u2013D1428). https:\/\/doi.org\/10.1093\/nar\/gkad806. PubMed: 37889037.","DOI":"10.1093\/nar\/gkad806"},{"key":"3719_CR9","doi-asserted-by":"publisher","first-page":"6723","DOI":"10.1093\/nar\/gkad470","volume":"51","author":"F Blandino","year":"2023","unstructured":"Blandino F et al. Phosphorylation status of MUS81 is a modifier of Olaparib sensitivity in BRCA2-deficient cells. Nucleic Acids Res. 2023;51:6723\u20136737. https:\/\/doi.org\/10.1093\/nar\/gkad470. PubMed: 37254810.","journal-title":"Nucleic Acids Res"},{"key":"3719_CR10","doi-asserted-by":"publisher","unstructured":"Wang Z, et al. Hsa_circ_0038737 promotes PARPi resistance in castration-resistant prostate cancer via IGF2BP3-mediated DNPH1 mRNA stabilization. Mol Cancer. 2025;24(238). https:\/\/doi.org\/10.1186\/s12943-025-02447-y. PubMed: 41039575.","DOI":"10.1186\/s12943-025-02447-y"},{"key":"3719_CR11","doi-asserted-by":"publisher","unstructured":"Teyssonneau D, et al. Prostate cancer and PARP inhibitors: Progress and challenges. J Hematol Oncol. 2021;14(51). https:\/\/doi.org\/10.1186\/s13045-021-01061-x. PubMed: 33781305.","DOI":"10.1186\/s13045-021-01061-x"},{"key":"3719_CR12","doi-asserted-by":"publisher","first-page":"100744","DOI":"10.1016\/j.drup.2021.100744","volume":"55","author":"M Chiappa","year":"2021","unstructured":"Chiappa M, Guffanti F, Bertoni F, Colombo I, Damia G. Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer. Drug Resist Updat. 2021;55:100744. https:\/\/doi.org\/10.1016\/j.drup.2021.100744. PubMed: 33551306.","journal-title":"Drug Resist Updat"},{"key":"3719_CR13","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/j.ccell.2024.10.015","volume":"42","author":"G Seed","year":"2024","unstructured":"Seed G et al. Elucidating acquired PARP inhibitor resistance in advanced prostate cancer. Cancer Cell. 2024;42:2113\u20132123.e4. https:\/\/doi.org\/10.1016\/j.ccell.2024.10.015. PubMed: 39577422.","journal-title":"Cancer Cell"},{"key":"3719_CR14","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.tcb.2017.11.006","volume":"28","author":"AJ Wolpaw","year":"2018","unstructured":"Wolpaw AJ, Dang CV. Exploiting metabolic vulnerabilities of cancer with precision and accuracy. Trends Cell Biol. 2018;28:201\u2013212. https:\/\/doi.org\/10.1016\/j.tcb.2017.11.006. PubMed: 29229182.","journal-title":"Trends Cell Biol"},{"key":"3719_CR15","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.molcel.2015.10.018","volume":"60","author":"GM DeNicola","year":"2015","unstructured":"DeNicola GM, Cantley LC. Cancer\u2019s fuel choice: New flavors for a picky eater. Mol Cell. 2015;60:514\u2013523. https:\/\/doi.org\/10.1016\/j.molcel.2015.10.018. PubMed: 26590711.","journal-title":"Mol Cell"},{"key":"3719_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","volume":"23","author":"NN Pavlova","year":"2016","unstructured":"Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23:27\u201347. https:\/\/doi.org\/10.1016\/j.cmet.2015.12.006. PubMed: 26771115.","journal-title":"Cell Metab"},{"key":"3719_CR17","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1172\/JCI132876","volume":"130","author":"J Liu","year":"2020","unstructured":"Liu J, et al. Parkin ubiquitinates phosphoglycerate dehydrogenase to suppress serine synthesis and tumor progression. J Clin Invest. 2020;130:3253\u201369. https:\/\/doi.org\/10.1172\/JCI132876. PubMed: 32478681.","journal-title":"J Clin Invest"},{"key":"3719_CR18","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.apsb.2021.06.008","volume":"12","author":"C Chen","year":"2022","unstructured":"Chen C, et al. Identification of a novel PHGDH covalent inhibitor by chemical proteomics and phenotypic profiling. Acta Pharm Sin B. 2022;12:246\u201361. https:\/\/doi.org\/10.1016\/j.apsb.2021.06.008. PubMed: 35127383.","journal-title":"Acta Pharm Sin B"},{"key":"3719_CR19","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/j.ccell.2022.09.014","volume":"40","author":"X Rovira-Clav\u00e9","year":"2022","unstructured":"Rovira-Clav\u00e9 X et al. Spatial epitope barcoding reveals clonal tumor patch behaviors. Cancer Cell. 2022;40:1423\u20131439.e11. https:\/\/doi.org\/10.1016\/j.ccell.2022.09.014. PubMed: 36240778.","journal-title":"Cancer Cell"},{"key":"3719_CR20","doi-asserted-by":"publisher","first-page":"eadj7540","DOI":"10.1126\/sciadv.adj7540","volume":"10","author":"ED Sunassee","year":"2024","unstructured":"Sunassee E, D, et al. Optical imaging reveals chemotherapy-induced metabolic reprogramming of residual disease and recurrence. Sci Adv. 2024;10:eadj7540. https:\/\/doi.org\/10.1126\/sciadv.adj7540. PubMed: 38579004.","journal-title":"Sci Adv"},{"key":"3719_CR21","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41586-024-08248-5","volume":"637","author":"J Jin","year":"2025","unstructured":"Jin J, et al. Human HDAC6 senses valine abundancy to regulate DNA damage. Nature. 2025;637:215\u201323. https:\/\/doi.org\/10.1038\/s41586-024-08248-5. PubMed: 39567688.","journal-title":"Nature"},{"key":"3719_CR22","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ccell.2019.12.011","volume":"37","author":"S Sivanand","year":"2020","unstructured":"Sivanand S, Vander Heiden MG. Emerging roles for branched-chain amino acid metabolism in cancer. Cancer Cell. 2020;37:147\u2013156). https:\/\/doi.org\/10.1016\/j.ccell.2019.12.011. PubMed: 32049045.","journal-title":"Cancer Cell"},{"key":"3719_CR23","doi-asserted-by":"publisher","first-page":"e165787","DOI":"10.1172\/JCI165787","volume":"134","author":"J Yang","year":"2024","unstructured":"Yang J et al. A BMP-controlled metabolic\/epigenetic signaling cascade directs midfacial morphogenesis. J Clin Invest. 2024;134:e165787. https:\/\/doi.org\/10.1172\/JCI165787. PubMed: 38466355.","journal-title":"J Clin Invest"},{"key":"3719_CR24","doi-asserted-by":"publisher","first-page":"eadc9465","DOI":"10.1126\/sciadv.adc9465","volume":"9","author":"M Fan","year":"2023","unstructured":"Fan M et al. Lactate promotes endothelial-to-mesenchymal transition via Snail1 lactylation after myocardial infarction. Sci Adv. 2023;9:eadc9465. https:\/\/doi.org\/10.1126\/sciadv.adc9465. PubMed: 36735787.","journal-title":"Sci Adv"},{"key":"3719_CR25","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/s41467-021-21186-4","volume":"12","author":"L Jiang","year":"2021","unstructured":"Jiang L, et al. Salmonella Typhimurium reprograms macrophage metabolism via T3SS effector SopE2 to promote intracellular replication and virulence. Nat Commun. 2021;12:879. https:\/\/doi.org\/10.1038\/s41467-021-21186-4. PubMed: 33563986.","journal-title":"Nat Commun"},{"key":"3719_CR26","doi-asserted-by":"publisher","unstructured":"Bo T, Fujii J. Primary roles of branched chain amino acids (BCAAs) and their metabolism in physiology and metabolic disorders. Molecules. 2024;30(56). https:\/\/doi.org\/10.3390\/molecules30010056. PubMed: 39795113.","DOI":"10.3390\/molecules30010056"},{"key":"3719_CR27","doi-asserted-by":"publisher","unstructured":"Mei W, et al. BCAT2 binding to PCBP1 regulates the PI3K\/AKT signaling pathway to inhibit autophagy-related apoptosis and ferroptosis in prostate cancer. Cell Death Dis. 2025;16(337). https:\/\/doi.org\/10.1038\/s41419-025-07559-3. PubMed: 40274762.","DOI":"10.1038\/s41419-025-07559-3"},{"key":"3719_CR28","doi-asserted-by":"publisher","first-page":"nwab212","DOI":"10.1093\/nsr\/nwab212","volume":"9","author":"JT Li","year":"2022","unstructured":"Li JT, et al. Diet high in branched-chain amino acid promotes PDAC development by USP1-mediated BCAT2 stabilization. Natl Sci Rev. 2022;9:nwab212. https:\/\/doi.org\/10.1093\/nsr\/nwab212. PubMed: 35663242.","journal-title":"Natl Sci Rev"},{"key":"3719_CR29","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1038\/s41467-021-23071-6","volume":"12","author":"EL Giddings","year":"2021","unstructured":"Giddings EL, et al. Mitochondrial ATP fuels ABC transporter-mediated drug efflux in cancer chemoresistance. Nat Commun. 2021;12:2804. https:\/\/doi.org\/10.1038\/s41467-021-23071-6. PubMed: 33990571.","journal-title":"Nat Commun"},{"key":"3719_CR30","doi-asserted-by":"publisher","first-page":"eadi6682","DOI":"10.1126\/scitranslmed.adi6682","volume":"16","author":"VD Dahik","year":"2024","unstructured":"Dahik VD et al. ABCG1 orchestrates adipose tissue macrophage plasticity and insulin resistance in obesity by rewiring saturated fatty acid pools. Sci Transl Med. 2024;16:eadi6682. https:\/\/doi.org\/10.1126\/scitranslmed.adi6682. PubMed: 39661702.","journal-title":"Sci Transl Med"},{"key":"3719_CR31","doi-asserted-by":"publisher","first-page":"17043","DOI":"10.1038\/celldisc.2017.43","volume":"3","author":"M Melikishvili","year":"2017","unstructured":"Melikishvili M, Chariker JH, Rouchka EC, Fondufe-Mittendorf YN. Transcriptome-wide identification of the RNA-binding landscape of the chromatin-associated protein PARP1 reveals functions in RNA biogenesis. Cell Discov. 2017;3:17043. https:\/\/doi.org\/10.1038\/celldisc.2017.43. PubMed: 29387452.","journal-title":"Cell Discov"},{"key":"3719_CR32","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.14670\/HH-11-633","volume":"30","author":"V Barresi","year":"2015","unstructured":"Barresi V, Reggiani Bonetti L, Ieni A, Caruso RA, Tuccari G. Histological grading in colorectal cancer: New insights and perspectives. Histol Histopathol. 2015;30:1059\u20131067. https:\/\/doi.org\/10.14670\/HH-11-633. PubMed: 26004398.","journal-title":"Histol Histopathol"},{"key":"3719_CR33","doi-asserted-by":"publisher","first-page":"10493","DOI":"10.1093\/nar\/gkab777","volume":"49","author":"LK Saha","year":"2021","unstructured":"Saha LK, et al. Replication-dependent cytotoxicity and Spartan-mediated repair of trapped PARP1-DNA complexes. Nucleic Acids Res. 2021;49:10493\u2013506. https:\/\/doi.org\/10.1093\/nar\/gkab777. PubMed: 34551432.","journal-title":"Nucleic Acids Res"},{"key":"3719_CR34","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12943-024-02025-8","volume":"23","author":"C Liu","year":"2024","unstructured":"Liu C, et al. PARP1-DOT1L transcription axis drives acquired resistance to PARP inhibitor in ovarian cancer. Mol Cancer. 2024;23:111. https:\/\/doi.org\/10.1186\/s12943-024-02025-8. PubMed: 38778348.","journal-title":"Mol Cancer"},{"key":"3719_CR35","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.tcb.2019.07.008","volume":"29","author":"SM van Noordermeer","year":"2019","unstructured":"Noordermeer SM, van Attikum H. PARP inhibitor resistance: A tug-of-war in BRCA-mutated cells. Trends Cell Biol. 2019;29:820\u2013834. https:\/\/doi.org\/10.1016\/j.tcb.2019.07.008. PubMed: 31421928.","journal-title":"Trends Cell Biol"},{"key":"3719_CR36","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.molcel.2010.06.017","volume":"39","author":"R Krishnakumar","year":"2010","unstructured":"Krishnakumar R, Kraus WL. The PARP side of the nucleus: Molecular actions, physiological outcomes, and clinical targets. Mol Cell. 2010;39:8\u201324. https:\/\/doi.org\/10.1016\/j.molcel.2010.06.017. PubMed: 20603072.","journal-title":"Mol Cell"},{"key":"3719_CR37","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.mam.2013.01.005","volume":"34","author":"WL Kraus","year":"2013","unstructured":"Kraus WL, Hottiger MO. PARP-1 and gene regulation: Progress and puzzles. Mol. Aspects Med. 2013;34:1109\u20131123. https:\/\/doi.org\/10.1016\/j.mam.2013.01.005. PubMed: 23357755.","journal-title":"Mol. Aspects Med"},{"key":"3719_CR38","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1038\/s41467-019-09174-1","volume":"10","author":"C Wang","year":"2019","unstructured":"Wang C, et al. Poly(ADP-ribose) polymerase 1 accelerates vascular calcification by upregulating Runx2. Nat Commun. 2019;10:1203. https:\/\/doi.org\/10.1038\/s41467-019-09174-1. PubMed: 30867423.","journal-title":"Nat Commun"},{"key":"3719_CR39","doi-asserted-by":"publisher","first-page":"7107","DOI":"10.3390\/ijms23137107","volume":"23","author":"EY Kotova","year":"2022","unstructured":"Kotova EY et al. Human PARP1 facilitates transcription through a nucleosome and histone displacement by Pol II in vitro. Int J Mol Sci. 2022;23:7107. https:\/\/doi.org\/10.3390\/ijms23137107. PubMed: 35806109.","journal-title":"Int J Mol Sci"},{"key":"3719_CR40","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.mam.2013.04.001","volume":"34","author":"C Thomas","year":"2013","unstructured":"Thomas C, Tulin AV. Poly-(ADP-ribose) polymerase: Machinery for nuclear processes. Mol Aspects Med. 2013;34:1124\u201337. https:\/\/doi.org\/10.1016\/j.mam.2013.04.001. PubMed: 23624145.","journal-title":"Mol Aspects Med"},{"key":"3719_CR41","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1126\/science.aaf7865","volume":"353","author":"BA Gibson","year":"2016","unstructured":"Gibson BA, et al. Chemical genetic discovery of PARP targets reveals a role for PARP-1 in transcription elongation. Science. 2016;353:45\u201350. https:\/\/doi.org\/10.1126\/science.aaf7865. PubMed: 27256882.","journal-title":"Science"},{"key":"3719_CR42","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.molcel.2011.11.015","volume":"45","author":"SJ Petesch","year":"2012","unstructured":"Petesch SJ, Lis JT. Activator-induced spread of poly(ADP-ribose) polymerase promotes nucleosome loss at Hsp70. Mol Cell. 2012;45:64\u201374. https:\/\/doi.org\/10.1016\/j.molcel.2011.11.015. PubMed: 22178397.","journal-title":"Mol Cell"},{"key":"3719_CR43","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.tig.2012.02.005","volume":"28","author":"SJ Petesch","year":"2012","unstructured":"Petesch SJ, Lis JT. Overcoming the nucleosome barrier during transcript elongation. Trends Genet. 2012;28:285\u201394. https:\/\/doi.org\/10.1016\/j.tig.2012.02.005. PubMed: 22465610.","journal-title":"Trends Genet"},{"key":"3719_CR44","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s41586-025-09414-z","volume":"645","author":"SC Moser","year":"2025","unstructured":"Moser SC, et al. NASP modulates histone turnover to drive PARP inhibitor resistance. Nature. 2025;645:1071\u201380. https:\/\/doi.org\/10.1038\/s41586-025-09414-z. PubMed: 40804522.","journal-title":"Nature"},{"key":"3719_CR45","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.molcel.2020.12.021","volume":"81","author":"K Challa","year":"2021","unstructured":"Challa K et al. Damage-induced chromatome dynamics link Ubiquitin ligase and proteasome recruitment to histone loss and efficient DNA repair. Mol Cell. 2021;81:811\u2013829.e6. https:\/\/doi.org\/10.1016\/j.molcel.2020.12.021. PubMed: 33529595.","journal-title":"Mol Cell"},{"key":"3719_CR46","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nsmb.3347","volume":"24","author":"MH Hauer","year":"2017","unstructured":"Hauer MH et al. Histone degradation in response to DNA damage enhances chromatin dynamics and recombination rates. Nat Struct Mol Biol. 2017;24:99\u2013107. https:\/\/doi.org\/10.1038\/nsmb.3347. PubMed: 28067915.","journal-title":"Nat Struct Mol Biol"},{"key":"3719_CR47","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/nrc3748","volume":"14","author":"S Vyas","year":"2014","unstructured":"Vyas S, Chang P. New PARP targets for cancer therapy. Nat Rev Cancer. 2014;14:502\u2013509. https:\/\/doi.org\/10.1038\/nrc3748. PubMed: 24898058.","journal-title":"Nat Rev Cancer"},{"key":"3719_CR48","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nrm3376","volume":"13","author":"BA Gibson","year":"2012","unstructured":"Gibson BA, Kraus WL. New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat Rev Mol Cell Biol. 2012;13:411\u2013424. https:\/\/doi.org\/10.1038\/nrm3376. PubMed: 22713970.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3719_CR49","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41556-021-00807-6","volume":"24","author":"DB Krastev","year":"2022","unstructured":"Krastev DB et al. The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin. Nat Cell Biol. 2022;24:62\u201373. https:\/\/doi.org\/10.1038\/s41556-021-00807-6. PubMed: 35013556.","journal-title":"Nat Cell Biol"},{"issue":"5","key":"3719_CR50","doi-asserted-by":"publisher","first-page":"e2515790122","DOI":"10.1073\/pnas.2515790122","volume":"123","author":"NA Traphagen","year":"2026","unstructured":"Traphagen NA et al. Lack of synergy between AR-targeted therapies and PARP inhibitors in homologous recombination-proficient prostate cancer. Proc Natl Acad Sci U S A. 2026;123(5):e2515790122. https:\/\/doi.org\/10.1073\/pnas.2515790122. PubMed: 41591905.","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03719-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03719-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03719-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T23:11:00Z","timestamp":1783033860000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-026-03719-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3719"],"URL":"https:\/\/doi.org\/10.1186\/s13046-026-03719-1","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"8 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal protocols in this study were reviewed and approved by the Animal Ethics Committee of Shanghai Tenth People\u2019s Hospital with approval number: SHDSYY-2025-6012 and performed in accordance with the policies of the State Ministry of Health. The use of clinical specimens was approved by the Ethics Committee of Shanghai East Hospital Affiliated to Tongji University with approval number: 2024YS-244. The project participant provided written consent. All study procedures were carried out in accordance with the Declaration of Helsinki. All participants were informed about the purpose of the study, assured of confidentiality, and provided written consent prior to participation. Participation was voluntary, and respondents could withdraw at any time without consequence.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All subjects have written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"149"}}